Description for medicine or protocol of treatment in detail:
|
(1) Traditional Chinese medicine treatment plan: referring to the diagnosis, syndrome differentiation and efficacy evaluation of chronic renal failure formulated by the nephrosis branch of the Chinese Academy of traditional Chinese medicine in 2006, and the traditional Chinese medicine diagnosis and treatment plan for 95 diseases in 22 majors issued and promoted by the medical administration department of the State Administration of traditional Chinese medicine in 2012, combined with the summary of clinical practice in the Department of Nephrology of the First Affiliated Hospital of Anhui University of traditional Chinese medicine for more than 20 years, Form a TCM Comprehensive Treatment Scheme Based on traditional Chinese medicine for the treatment of ckd3-4. The specific scheme includes the following contents:
① Compound granules (main traditional Chinese medicine treatment scheme, must be used): use compound granules that strengthen the spleen and kidney, remove blood stasis and discharge turbidity: 30g Radix Astragali, 20g Radix Codonopsis Pilosulae, 10g Cornus meat, cooked land, Fu Ling skin, Alisma orientalis, plantain, wax gourd skin, angelica, raw rhubarb, 30g corncob and Salvia miltiorrhiza. Usage: take it gently after brewing with boiling water, 1 dose per day, and take it orally twice in the morning and evening.
If it is not spleen and kidney deficiency with blood stasis, please refer to the diagnosis, syndrome differentiation and efficacy evaluation of chronic renal failure and the TCM diagnosis and treatment plan of 95 diseases in 22 majors for syndrome differentiation and treatment.
② Suitable techniques of traditional Chinese medicine (optional according to the actual clinical application): Traditional Chinese medicine retention enema, colon dialysis, etc.
③ Chinese patent medicine (optional according to the actual clinical application): Shenshuaining capsule, Niaoduqing granule, Haikun Shenxi Capsule, Cordyceps preparation (bailing capsule, Jinshuibao tablet), etc.
(2) Western medicine treatment plan (refer to relevant guidelines and expert consensus), including:
① Dietary nutrition (refer to the clinical practice guide for nutritional treatment of chronic kidney disease in China, 2021 Edition);
② Control blood pressure (refer to the 2018 guidelines for the prevention and treatment of hypertension in China);
③ Correct anemia (Chinese clinical practice guide for the diagnosis and treatment of renal anemia, 2021);
④ Prevention and treatment of abnormal mineral and bone metabolism (CKD-MBD) (2017 KDIGO CKD-MBD clinical practice guide);
⑤ Regulate water, electrolyte and acid-base metabolic balance.
Western medicine treatment group: use western medicine treatment scheme;
Treatment group of integrated traditional Chinese and Western medicine: add traditional Chinese medicine treatment scheme on the basis of Western medicine treatment scheme.
Treatment cycle: the continuous treatment and observation cycle is 2 years.
|
Inclusion criteria
|
① Age 18 ~ 70 years old, ② meet the diagnostic criteria of CKD stage 3-4; ③ Blood pressure < 140/90mmhg, blood potassium < 5.5mmol/l, hemoglobin ≥ 80g/l, infection was controlled, and the condition was stable for more than 2 weeks; ④ Those who did not use Chinese patent medicine for CKD within 2 weeks before enrollment, or who had used Chinese patent medicine but had a 2-week washout period; ⑤ Sign informed consent.
|
Exclusion criteria:
|
① Pregnant or lactating patients ② unable to cooperate, such as psychotic patients ③ complicated with active malignant tumors, infectious diseases, liver cirrhosis decompensation, hematopoietic system and other serious primary diseases; ④ There is acute urinary tract obstructive disease, which needs surgical treatment; ⑤ Severe arrhythmia, heart failure, NYHA grade III or above, or myocardial infarction or cerebrovascular events within 3 months before enrollment; ⑥ Using corticosteroids, non steroidal anti-inflammatory drugs or immunosuppressants; ⑦ Accord with the clinical or pathological diagnosis of diabetes kidney disease; ⑧ Patients are unwilling to participate and refuse to sign informed consent; ⑨ Patients who are participating in other clinical trials
|